There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Orchestra BioMed Holdings (OBIO – Research Report), Anavex Life Sciences (AVXL – Research Report) and Recursion Pharmaceuticals (RXRX – Research Report) with bullish sentiments.
Orchestra BioMed Holdings (OBIO)
LifeSci Capital analyst Rahul Rakhit maintained a Buy rating on Orchestra BioMed Holdings today and set a price target of $21.00. The company’s shares closed last Tuesday at $5.61, close to its 52-week low of $5.19.
According to TipRanks.com, Rakhit is ranked #8480 out of 8551 analysts.
Currently, the analyst consensus on Orchestra BioMed Holdings is a Moderate Buy with an average price target of $20.50.
See today’s best-performing stocks on TipRanks >>
Anavex Life Sciences (AVXL)
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Anavex Life Sciences, with a price target of $58.00. The company’s shares closed last Tuesday at $7.67, close to its 52-week low of $7.44.
According to TipRanks.com, Roy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Anavex Life Sciences is a Strong Buy with an average price target of $50.67, a 533.4% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $54.00 price target.
Recursion Pharmaceuticals (RXRX)
In a report released today, Gaurav Goparaju from Berenberg Bank maintained a Buy rating on Recursion Pharmaceuticals, with a price target of $35.00. The company’s shares closed last Tuesday at $11.02.
According to TipRanks.com, Goparaju has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Recursion Pharmaceuticals with a $16.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on OBIO:
